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in female breast cancer patients (n = 12) before and after 
three cycles of polychemotherapy regimes containing CP.
Results OzVal-Hb, a specific and stable biomarker, could 
be measured with great sensitivity (lower limit of quantifi-
cation = 33 pmol g−1 Hb), high accuracy (within ±20 %) 
and good repeatability (CV < 20 %). the inter-individual 
variability in the blood level of this adduct in women with 
breast cancer (n = 12) who received three doses of CP in 
combination with one or two other cytostatic drugs was 
250 % following the first dose and approximately 150 % 
after each subsequent dose.
Conclusions Measurement of the biomarker OzVal-Hb 
can be used to quantify the short-lived cytotoxic agent 
PaM in a single blood sample drawn several days after 
therapy. this procedure may aid in individualizing doses of 
CP, thereby improving efficacy while both reducing the risk 
of and increasing the predictability of side-effects.
Keywords Cyclophosphamide · Phosphoramide 
mustard · Personalized cancer medicine · Hemoglobin 
adducts · therapeutic drug monitoring · tDM
Introduction
In general, dosing of cytostatic drugs is based on the 
patient’s body surface area (BSa, mg m−2) or weight 
(mg kg−1), although little evidence actually validates these 
approaches [1, 2]. the major concern is that such average 
optimal BSa dosing for a large group of patients does not 
take into account individual variations in metabolism and 
rate of clearance.
the cytostatic prodrug cyclophosphamide (CP) must 
be metabolized to obtain the active agent. this involves 
hydroxylation in the liver to form the unstable precursor 
Abstract 
Purpose Use of the patient’s body surface area (mg m−2) 
as a basis for dosing does not take individual variation in 
metabolic capacity and rate of clearance into account. Here, 
we evaluated a novel approach for individual monitoring of 
short-lived cytotoxic agents formed from cytostatic drugs 
such as cyclophosphamide (CP).
Methods the accumulated blood dose of the cytotoxic 
active agent phosphoramide mustard (PaM) formed from 
CP was measured as a reaction product with hemoglobin 
(Hb adduct). this adduct, N-[2-(2-oxazolidonyl)ethyl]-
valyl Hb (OzVal-Hb), was detached from Hb with the 
adduct FIRe procedure™, and the formed analyte was 
quantified using lC-MS/MS. this dose biomarker for PaM 
and the analytical procedure was evaluated in accordance 
with the guidelines on bioanalytical method validation for-
mulated by the european Medicine agency. the evaluated 
method was applied to quantify blood dose levels of PaM 
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4-hydroxy cyclophosphamide (4-OH-CP), the rate of 
which can vary tenfold between individuals [3, 4]. Part of 
this product diffuses through membranes into the nucleus, 
where it decomposes to the cytotoxic phosphoramide 
mustard (PaM) [5]. no clinical assay for direct measure-
ment of PaM is presently available. Instead, the precursor, 
4-OH-CP, is commonly measured after extraction and deri-
vatization [3, 4]. also, acrolein, which is generated when 
aldophosphamide, the ring-opened tautomer of 4-OH-CP, 
decomposes to PaM [5–8], has been used to estimate the 
concentration of PaM. this lack of a clinical assay for 
determination of the area under the plasma concentra-
tion–time curve (aUC) of PaM is problematic, since the 
difference between the concentration of a cytostatic drug 
required for efficacy and that which causes severe toxicity 
to vital organs is often small [8]. thus, many patients may 
be under- or overdosed with CP.
a more effective and safer approach is therapeutic dose 
monitoring (tDM), which involves determination of the 
internal level of the cytostatic agent in an individual and 
adjustment of the dose on the basis of this value. However, 
tDM is rarely employed, since the traditional analyti-
cal procedures currently available require multiple blood 
samples to obtain the aUC. Moreover, metabolites such as 
PaM, which exhibits a short half-life in patients (14 min 
[7]), occurs at low concentrations and is difficult to isolate 
from blood (in this case because of its ionic nature), are 
exceedingly difficult to quantify.
While the desired cytotoxic effect of PaM arises from 
its reaction with Dna, this active electrophilic metabo-
lite also reacts with other biomacromolecules, including 
proteins. Many electrophiles bind covalently to the nucle-
ophilic n-terminal valine residue in hemoglobin (Hb) 
to form so-called adducts. Since 1986, quantification of 
n-terminal Hb adducts employing the N-alkyl edman 
procedure and slightly modified variants thereof has been 
applied to monitor industrial exposure in humans, as well 
as low-level chemical exposure in general human popula-
tions [9, 10].
to date, this approach has not been utilized by oncolo-
gists to measure internal doses of chemically reactive 
drugs/metabolites in humans. One reason for this may be 
the low rate of sample throughput due to the many time-
consuming steps involved, in combination with the com-
plex analytical setup. thulin et al. [11] developed the 
N-alkyl procedure further to successfully measure protein 
adducts formed from both CP and nornitrogen mustard 
(nnM) in mice, as well as from nnM in a hemolysate in 
vitro. the N-[2-(2-oxazolidonyl)ethyl]-valyl Hb (OzVal-
Hb) adduct can only be formed from bisalkylating agents, 
i.e., PaM or its hydrolysis product nnM, as suggested 
by the mechanism in Fig. 1. Formation of this adduct is 
favored by a high concentration of CO2/HCO3 in the blood.
In attempt to overcome the shortcomings of the N-alkyl 
edman procedure, the adduct FIRe procedure™ was devel-
oped [12, 13]. Since this procedure was designed and opti-
mized for detection by lC–MS/MS, polar, ionic and ther-
molabile adducts can be measured directly without prior 
derivatization [12, 13]. However, its major advantage is the 
20-fold higher rate of sample throughput in the complete 
analytical chain (96 samples processed/3 days), allowing its 



















































Fig. 1  Proposed metabolism of CP to 4-OH-CP, followed by degradation to PaM, which then reacts with the n-terminus of hemoglobin (Hb) 
followed by incorporation of carbon dioxide to form the stable OzVal-Hb adduct
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more than thousands of newborn infants [16, 17] and, in the 
very near future, for clinical applications within oncology.
Our present aim was to adapt, optimize and validate meas-
urement of OzVal-Hb adducts by the FIRe procedure™. the 
procedure was evaluated for selectivity, carryover, lower 
limit of quantification (llOQ), accuracy, precision, matrix 
effects and stability, in accordance with the guidelines on 
bioanalytical method validation [18] formulated by the euro-
pean Medicine agency. to further evaluate the potential 
applicability of this method, 12 breast cancer patients were 
monitored before and after three cycles of dosing with CP. 
the obtained levels of OzVal-Hb adduct measured after the 
first dose was compared to hematological markers for tox-
icity such as the relative decrease of WBC and neutrophils 
measured day 8 after treatments and Hb levels after dose 
cycle three versus baseline values. this novel approach to 
quantifying active cytotoxic compounds such as PaM, that 
are designed to damage Dna by measuring a stable and spe-
cific hemoglobin adduct, is illustrated in Fig. 2.
Patients and experimental design
Patients
twelve patients with breast cancer receiving chemotherapy in 
connection with a randomized phase III study (PantHer, 
eudraCt number 2007-002061-12 and govtrials number 
nCt00798070 including over 2,000 patients) were divided 
equally into two study groups. all patients gave written 
informed consent prior to enrollment. this study was pre-
approved by the regional ethics review Board in Stockholm, 
Sweden (amendment to SBg2004-1, Dnr: 2009/1023-32).
the patients in group a received tailored therapy; dose 
adjustment based on the individual evaluation of laboratorial 
and clinical toxicity, using common toxicity criteria (CtC) at 
each course. the starting doses were epirubicin 90 mg m−2 
and cyclophosphamide 600 mg m−2 BSa. In connection 
with the second and third treatments, administered 2 and 
4 weeks later, the dose of CP was adjusted upward, to a max-
imum of 900 mg (n = 5) and 1,200 mg m−2 (n = 4), respec-
tively, and the maximal epirubicin dose was 120 mg m−2 
BSa. the patients in group B received three BSa-adjusted 
doses of 5-fluorouracil, epirubicin and cyclophosphamide 
(F500e100C500) at 3-week intervals followed by docetaxel. 
Demographic and clinical characteristics of studied patients 
are given as supplementary data (Supplementary table 1).
Blood samples
Blood samples collected from each patient before the first 
treatment and 14 or 21 days after the first, second and third 
cycles of dosing were stored at −20 °C until analysis. Com-
mercially available human blood (Karolinska University 
Hospital, Stockholm, Sweden), stored in the same manner, 
was used as a control, as well as to obtain a reference. to 
produce the reference, lysed whole blood was alkylated 
with 4-OOH-CP (150 µg ml−1, 16 h, 37 °C), a commonly 
used precursor to 4-hydroxycyclophosphamide (4-OH-CP). 
Subsequent dilution with whole control blood gave samples 
containing low, medium and high levels of the OzVal-Hb 
adduct (42, 87 and 162 pmol g−1 Hb, respectively).
Chemicals and reagents
Fluoresceine-5-isothiocyanate (FItC; isomer I. >90 % 
purity) and the analytical standards fluorescein-5-[4-
isopropyl-3-N-(2-(2-oxazolidonyl)ethyl)-2-thioxo-imi-
dazolidin-5-one] (OzVal-FtH, 97 % purity), fluores-
cein-5-[4-13C5-isopropyl-3-15N-(2-(2-oxazolidonyl)
Fig. 2  Biotransformation of CP to PaM, which cross-links Dna to achieve the cytotoxic effect and, in a parallel reaction, forms a stable Hb 
adduct which can be quantified by the FIRe procedure™ to obtain a measure of the internal dose of PaM in rBC accumulated over time
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ethyl)-2-thioxo-imidazolidin-5-one] (Oz-13C515n-Val-FtH, 
97 % purity) as well as the peptide adducts N-[2-(2-oxazo-
lidonyl)ethyl]-valyl-leucyl-anilide (Oz-Vla, 97 % purity) 
and N-[2-(2-oxazolidonyl)ethyl]-13C515n-valyl-leucyl-ani-
lide (Oz-13C515n-Vla, 97 % purity) were obtained from 
adduct analys aB (enebyberg, Sweden). 4-Hydroperoxy-
cyclophosphamide (4-OOH-CP) was a gift from Baxter 
(Baxter Deutschland gmbH). all other chemicals and sol-
vents employed were of analytical grade.
Quantification of OzVal-Hb levels utilizing the FIRe 
procedure™
the FIRe procedure™ was optimized for quantification of 
OzVal-Hb adduct as described below. Since this procedure 
utilizes fluorescein isothiocyanate (FItC) as the edman 
reagent, derivatization could be performed directly with 
unprocessed blood and the analytes formed isolated by pro-
tein precipitation and purified on mix-mode SPe columns. 
the key steps in the measurement of in vivo levels of PaM 
with the FIRe procedure™ are depicted in Supplementary 
Fig. 1.
For determination of the OzVal-Hb adducts, the Hb 
concentration in each sample was first measured with an 
Hb201 + HemoQue instrument (HemoQue, Ängelholm, 
Sweden) and thereafter, Oz-13C515n-Vla (20 pmol) was 
added to the blood (250 µl) as an internal standard. next, 
FItC (3 mg in 30 µl dimethylformamide) was added and 
the samples heated and mixed (40 °C, 750 rpm, 8 h). ace-
tonitrile (1.5 ml) was subsequently added to precipitate the 
proteins, followed by centrifugation (5 min, 20,000×g; 
Heraeus Pico 21 Microcentrifuge, thermo Scientific, lan-
genselbold, germany).
ammonium hydroxide (1 M, 15 µl) was added to the 
supernatant thus obtained before pouring it into a solid-
phase extraction mixed-mode anion-exchange cartridge 
(Oasis MaX, 60 mg sorbent weight, Waters, Massa-
chusetts, USa). the resin was washed with acetonitrile 
(1.5 ml), water (1.5 ml) and 0.25 % cyanoacetic acid in 
acetonitrile/water [3:7 (v/v), 1.5 ml] prior to elution of the 
analytes with 0.25 % cyanoacetic acid in water/acetoni-
trile [4:6 (v/v), 1.4 ml]. a gentle stream of air was used to 
remove all solvents from this eluate and the solid residue 
then dissolved in water/acetonitrile [7:3 (v/v), 100 µl] prior 
to analysis (20 µl) with lC/MS.
the lC/MS setup consisted of a Shimadzu Promi-
nence lC 20 system interfaced with a Sciex aPI 3200 
Q-trap instrument. the mobile phase consisting of 
0.1 % formic acid in acetonitrile/water [1:1 (v/v)] was 
passed with isocratic flow (0.12 ml min−1) through a 
X-select HSS t3 column (50 × 4.6 mm, 3 µm) (Waters) 
or a discovery HS C18 column (150 × 2.1 mm, 3 µm; 
Supelco analytical). the analysis was performed in the 
positive ion mode (eSI+) using multiple reaction monitor-
ing (MrM) at the following transitions: OzVal-FtH m/z 
602.2 → 563.2; 602.2 → 460.2; and Oz-13C515n-Val-FtH 
m/z 608.2 → 563.2; 608.2 → 463.2.
Optimization of adduct analysis
On the basis of earlier optimization of the FIRe proce-
dure™ for the determination of other types of Hb adducts 
[14, 17], a number of parameters were chosen for examina-
tion here. Since ionization of FItC requires one equivalent 
of base, different amounts of KHCO3 (0.050–4.4 mmol g−1 
Hb) were added to alkylated reference blood samples 
(n = 7, analysis in triplicate) immediately prior to the addi-
tion of FItC. Subsequent work-up and analysis were per-
formed as described above.
to evaluate the relationship between the amount of 
FItC added and yield of OzVal-Hb adduct, alkylated refer-
ence blood (250 µl) was incubated (in triplicate) with dif-
ferent amounts of this reagent (0.11, 0.15, 0.20, 0.26, 0.35 
and 0.47 mmol g−1 Hb) followed by the standard procedure 
described above.
the yield obtained with different periods of incubation 
(1, 2, 4, 8, 16 and 24 h, in quadruplicate) at 40 °C followed 
by storage at −20 °C, and further standard processing 
(within 24 h of derivatization) was also examined.
For elution of the analytes, cyanoacetic acid, formic 
acid and trifluoroacetic acid, as well as different relative 
amounts of the organic phase were compared.
Validation of our procedure
In accordance with the guidelines on bioanalytical method 
validation (2011) formulated by the european Medicine 
agency [18], our procedure was evaluated for selectivity, car-
ryover, llOQ, accuracy, precision, matrix effects and stability.
Selectivity was addressed by measuring OzVal-Hb 
adduct in blood samples from patients (n = 12) prior to 
their treatment with CP, as well as following incubation 
of control blood with the precursor of PaM, 4-OOH-CP 
in vitro. For the latter incubations, 250 µl each of six indi-
vidual blood samples, taken before treatment and not lysed, 
were incubated (in duplicate) in 2-ml eppendorf vials with 
four different concentrations of 4-OOH-CP (1.5, 4.4, 13 
and 40 µg ml−1; obtained by evaporation of an appropri-
ate amount of a stock solution of 1 mg ml−1 in dry tHF). 
these samples were stirred and incubated at 37 °C for 2 h, 
with parallel incubations of lysed samples, and then stored 
at −20 °C until analysis.
Carryover was examined by analyzing a blank sample 
immediately after determination of the highest concentra-
tion on the calibration curve, as well as after running the 
patient samples containing the highest levels of adduct.
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Solutions for calibration were prepared by adding the Oz 
adduct of dipeptides (Oz-Vla; 4, 8, 20, 40, 80, 200 and 
400 pmol ml−1) and the stably labeled internal standard 
Oz-13C515n-Vla (40 pmol ml−1 blood) to control blood. 
the areas under the peaks (OzVal-FtH/Oz13C515n-Val-FtH 
ratios) were plotted against concentration of Oz-Vla and 
the resulting curves drawn by linear regression analysis. 
the criterion for the llOQ was a signal-to-noise ratio >10 
and a deviation from the nominal value of less than 20 %.
employing control blood spiked with Oz-Vla at con-
centrations of 4, 8, 40 and 200 pmol ml−1, the within-run 
accuracy was evaluated by analyzing five samples at each 
concentration and the between-run accuracy by compar-
ing samples processed on three different days. Precision 
was determined utilizing these same samples, as well 
as by repeated analysis of control blood incubated with 
4-OOH-CP.
Potential matrix effects were addressed by adding 
OzVal-FtH (20 and 200 pmol ml−1) to processed blood 
samples (from six individual patients, prior to treatment), 
after the cleanup procedure and prior to lC–MS analysis, 
and comparison with standard solutions containing the 
same concentrations of OzVal-FtH.
the stability of the reference standards was examined by 
analyzing their retention times and the potential formation 
of new peaks with lC–UV (254 nm) and lC–MS (eSI+, 
full scan m/z 50–1,000).
to determine the influence of storage conditions on the 
stability of the OzVal-Hb adduct, blood from six patients 
was first stored at room temperature for up to 7 days (one 
sample from each patient per day, 1–7 days), then frozen to 
−20 °C and thereafter subjected to three cycles of freeze–
thawing (n = 6) or stored for 12 months at −20 °C (n = 6) 
prior to analysis. the potential effect of different levels of 
Hb (obtained by adding separated red blood cells to plasma 
from the same individual) in the blood during derivatiza-
tion and processing was also evaluated (n = 6).
Statistical analysis
Spearman’s correlation coefficients were used to assess 
correlations between obtained concentrations of OzVal-
Hb adduct and hematological markers for toxicity such as 
relative decrease in white blood cells count and neutrophils 
measured day 8 and decrease in Hb levels during treatment. 
two-sided p < 0.05 was considered statistically significant. 
Data were analyzed using IBM SPSS statistics, version 22 
(IBM Corp, new York, USa).
Results
Identification of a stable OzVal-Hb adduct formed 
from PaM
In blood samples from patients treated with CP, as well 
as in control blood samples incubated with 4-OOH-CP, 
the OzVal-Hb adduct was easily detected. Following deri-
vatization and detachment with the FIRe procedure™, 
the OzVal-Hb adduct was characterized by lC–MS in 
the MrM mode and its structure confirmed by compari-
son with authentic reference standards (Fig. 3). With this 
approach, the adduct could be detected and quantified in 
the blood of all the patients after, but not before, the treat-
ment with CP.
Optimization of the analytical procedure
altering the buffer capacity of the blood by addition of 
KHCO3 prior to the coupling reaction did not enhance 
+EPI (602.3) CE (65) 













































































Fig. 3  lC-MS/MS (eSI+, enhanced product ion scan) spectra of OzVal-FtH illustrating interpretation of the major fragments (left). Chromato-
gram illustrating the MrM transitions for OzVal-FtH and the internal standard Oz-13C515n-Val-FtH (right)
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the yield of adduct. Indeed, addition of KHCO3 in molar 
amounts equal to or in excess of FItC (see “Quantification 
of OzVal-Hb levels utilizing the FIRe procedure™” sec-
tion) actually reduced this yield by enhancing ion suppres-
sion during the lC/MS analysis.
Use of 0.26 mmol FItC per g Hb (approximately 3 mg 
per 250 µl blood) gave the optimal yield, with a 25 % 
reduction in the level of FItC lowering the yield of OzVal-
FtH by 10 % (SD 7 %; Supplementary Fig. 2).
the yield of OzVal-FtH was maximal following 8 h of 
incubation at 40 °C (Supplementary Fig. 3). this figure 
also reveals that the ratio of products to internal standard 
was remarkably similar at all time-points.
addition of known amounts of OzVal-FtH 
(5 pmol/250 µl; n = 6), before and after processing of blank 
control samples, revealed that the overall recovery during 
the cleanup procedure (including protein precipitation, SPe 
cleaning and evaporation of the solvent in the eluent from 
the SPe columns) was 74 % (4 % SD) and that ion suppres-
sion normalized to the internal standard was insignificant 
[−3 % (8 % SD)]. this recovery was not improved by elut-
ing the sample from the SPe column with a solution con-
taining more than 60 % acetonitrile or by modification of 
the pH (with 1 % CnHOaC, 0.25 % formic acid or 0.25 % 
trifluoroacetic acid) during the cleanup procedure. How-
ever, addition of 0.25 % CnHOaC to the solution used for 
elution reduced the risk of precipitation in the processed 
samples during storage.
Validation of the analytical procedure
Selectivity
analysis of solvent blanks and blood samples taken from 
patients prior to treatment with CP revealed no peaks 
with retention times similar to those expected for OzVal-
FtH or Oz-13C515n-Val-FtH. nor was any carryover effect 
observed when blank samples were injected following 
analysis of samples containing high levels of the adduct.
Formation of the oxazolidonyl adduct involves addition 
of carbon dioxide (Fig. 1). this adduct could in theory also 
be produced when dissolved HCO3− reacts as a nucleophile 
on a formed aziridine intermediate followed by subsequent 
ring-closure and elimination of water. to clarify whether this 
step, addition of CO2, influences the rate of adduct formation 
(yield), control blood was incubated with low to very high 
concentrations of 4-OOH-CP (far above those of clinical 
relevance) and formation of OzVal-Hb adduct was observed 
to be linearly dependent on the amount of 4-OOH-CP pre-
sent, with no decline at the higher concentrations (Fig. 4). 
Moreover, incubation of clinically relevant concentrations 
of 4-OOH-CP with six individual samples of fresh blood 
revealed a virtually identical relationship, with small individ-
ual variations (Fig. 4). However, 4-OOH-CP was not stable 
in freshly distilled dry tHF, as indicated by the lower abso-
lute levels of adducts in both patient and control samples 
analyzed with a solution of 4-OOH-CP that had been stored 
(approximately 46 % reduction following 30 days of storage 
at −20 °C). However, the ratio of the adduct levels in patient 
samples and frozen control blood remained the same (mean 
ratio 0.52, rSD 12.8 %) even after 30 days storage.
The calibration curve
to quantify as accurately as possible, dipeptide adducts 
(Oz-Vla) were employed for calibration and Oz-13C515n-
Vla as the internal standard and a linear fit applied to 
obtain the calibration curve. the lowest concentration 
on this curve was defined as the llOQ and found to be 
4.0 pmol ml−1 blood (33 pmol g−1 Hb). the lOD (with a 
signal-to-noise ratio of three) calculated from the signal-to-
noise ratio of the llOQ was approximately 4 pmol g−1 Hb. 
Back calculations of concentration were all within ±15 % 














































4-OOH-CP (µg mL-1 blood)
Fig. 4  Correlation between formation of the OzVal-Hb adduct in blood samples from six individual patients taken prior to treatment and con-
centrations of 4-OOH-CP. Left levels relevant for CP therapy. Right levels from below to above therapeutic doses
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Precision and accuracy
as documented in table 1, precision with control blood 
samples spiked with known amounts of Oz-Vla was bet-
ter than 15 % of the CV in all cases, except for the within-
run precision at a concentration equal to the llOQ, which 
was 18 %. the between-run and within-run precisions for 
all control blood samples incubated with 4-OOH-CP were 
better than 15 %. employing the Oz-Vla peptide as a sur-
rogate for n-terminal OzVal-Hb, accuracy was found to be 
within ±15 % of the nominal values, except for the within-
run accuracy at llOQ which was ±16 % of the nominal 
value.
Matrix effects
as evaluated with processed control blood samples from 
six individual patients containing low and high concentra-
tions of the analyte, a matrix effect for both the analyte 
and internal standard could not be avoided, despite cleanup 
with the analytical column prior to MS. However, since this 
matrix effect normalized to the internal standard was close 
to one, with an acceptable CV (<±15 %; table 1), this fac-
tor is not expected to influence quantification of the abso-
lute levels to any significant extent.
Stability and robustness
When blood samples (250 µl, n = 6) from patients treated 
with CP were left at room temperature for as long as 7 days 
before freezing, no significant effect (<20 %) on the adduct 
levels detected was observed. Moreover, the OzVal-Hb 
adduct was stable during three cycles of freeze/thawing 
(<20 % change; n = 6). Following storage for 12 months at 
−20 °C (n = 6), the ratio between the level of analyte and 
internal standard was only altered by 3.1 % (CV = 19 %).
Samples must be lysed to allow FItC to react with the 
n-terminus of Hb, and the relative effectiveness of freeze/
thawing with or without subsequent sonication in this con-
nection were compared. Sonication for 5, 15, 30 or 60 min 
after lysing and before further processing had no influence 
on the results obtained (Pearson’s correlation = −0.14, 
p = 0.56, n = 6).
Once OzVal-FtH was formed by derivatization, nei-
ther storage for 24 h at −20, +6 or +37 °C, nor precipita-
tion with acetonitrile at room temperature prior to further 
cleanup influenced the level of adduct detected (t tests, 
p ≥ 0.43).
Dilution of red blood cells from patients with their own 
plasma to obtain different concentrations of Hb had no 
apparent effect on the level of OzVal-Hb adduct subse-
quently detected (Supplementary Fig. 4).
reanalysis of processed samples following storage for 
72 h at −20 °C or in an autosampler at room temperature 
altered the results obtained by <20 %.
analysis by lC–UV–MS revealed no degradation prod-
ucts of the reference standard Oz-Vla or Oz-13C515n-Vla 
following storage in 2-propanol/H2O (3:7) at −20 °C or 
+8 °C for 6 months or at −20 °C for 12 months.
Levels of the OzVal‑Hb adduct in patients being treated 
with CP
the levels of OzVal-Hb adducts in blood collected from 
patients before treatment and after three subsequent 
cycles of dosing with either 500 mg CP m−2 BSa (group 
B, n = 6) or one 600 mg dose of CP m−2 BSa followed 
by biweekly stepwise increases based on individual toxic 
Table 1  Matrix factors (MF) for the OzVal-FtH analytes, precision and accuracy of our analyses of different concentrations of Oz-Vla  
dipeptide, and precision with control samples incubated with 4-OOH-CP
Oz-Vla peptide [pmol ml−1 blood]









Between-run precision, CV (%, n = 3) 7.5 3.9 8.9 12.6
Within-run precision, CV (%, n = 6) 18.0 11.1 13.6 9.2
Between-run accuracy, % (CV, n = 3) 105 (7.8) 110 (4.2) 104 (9.3) 97.1 (12.2)
Within-run accuracy, % (CV, n = 6) 116 (19.1) 91.6 (9.2) 95.2 (11.8) 95.5 (8.0)
Blood incubated with 4-OHCP adduct level low Medium High
Between-run precision, CV (%, n = 3) 12.9 7.0 6.0
Within-run precision, CV (%, n = 4) 2.6 6.5 3.5
Matrix factor at [20 pmol ml−1] CV (%, n = 6) [200 pmol ml−1] CV (%, n = 6)
OzVal-FtH 0.66 14.9 0.61 3.4
Oz-13C515n-Val-FtH 0.67 17.7 0.59 7.5
normalized to the internal standard 0.99 12.6 1.06 9.0
556 Cancer Chemother Pharmacol (2014) 74:549–558
1 3
response (group a, n = 6) were determined. Following 
the first dose, the mean level of adducts differed by 24 % 
between groups a and B, in agreement with the amount of 
CP administered. the difference between the patients with 
the highest and lowest values was approximately 250 % 
after the first dose and 150 % after each subsequent dos-
ing cycle (Fig. 5). the patients exhibiting lower or higher 
levels after the first dose continued to do so following the 
second and third dose cycles as well. no background levels 
or interfering peaks were present in the samples collected 
prior to treatment with CP.
Relation between measured OzVal‑Hb adduct level 
and hematologic variables
In dose group B, a negative trend was observed between 
OzVal-Hb adduct measured after the first dose and relative 
decrease of WBC (rs = −0.66, p = 0.16, n = 6) and neu-
trophils (rs = −0.46, p = 0.35, n = 6) measured day 8 
after treatments and Hb levels after dose cycle three versus 
baseline values (rs = −0.83, p = 0.04, n = 6). In group 
a, there was no clear trend observed. Data are given in 
Supplementary table 2.
Discussion
We have demonstrated that the FIRe procedure™ can be 
applied to quantify the OzVal-Hb adduct as an indicator 
of the level of the reactive and cytotoxic metabolite PaM 
formed in vivo from CP. Our custom designed procedure 
is robust in terms of selectivity, linearity, accuracy, preci-
sion and stability and thus fulfills all the criteria for vali-
dation presented in the guidelines on bioanalytical method 
validation (2011) formulated by the european Medicine 
agency.
the optimal amount of FItC found here represents a 
compromise between a good yield of thiohydantoin and 
occurrence of side reactions that lead to ion suppression. 
although a reaction time of 16 h provided the highest yield 
of analyte, the ratio of the level of analyte to that of the 
internal standard was independent of reaction time. this 
indicates that use of the dipeptide containing a stable iso-
tope (Oz-13C515n-Vla) represents a robust approach to 
quantification.
to form the OzVal-Hb adduct, PaM first reacts with 
the n-terminal valine in Hb and then CO2 is incorporated, 
which subsequently deactivates the last reactive function-
ality through alkylation of the carboxylate, rendering the 
OzVal-Hb adduct chemically stable under physiological 
conditions. In all three individual blood samples exam-
ined, the formation of OzVal-Hb adduct was linearly pro-
portional to the amount of 4-OOH-CP present. In order to 
compensate for degradation of 4-OOH-CP dissolved in a 
stock solution (dry tHF, stored at −20 °C <5 days), refer-
ence blood samples were incubated in parallel.
Presumably, more than 99 % of the 4-OH-CP formed 
from 4-OOH-CP had reacted after 2 h of incubation. the 
patient samples were fresh whole blood, whereas the con-
trol samples were lysed blood, which resulted in a ratio of 
0.52 between the adduct levels in these samples. no back-
ground levels of OzVal-Hb adducts or interfering peaks 
were observed.
Some specific adaptation of the guidelines for validation 
was necessary, since a well-defined Oz-Hb standard (con-
taining a known level of adduct) is not commercially acces-
sible. as a surrogate, the peptide Oz-Vla was employed 
for quantification and determination of accuracy. the 
studies on precision were also complemented by repeated 
measurements of alkylated reference samples. With both of 
these approaches, the results were acceptable according to 
the guidelines.
In both alkylated reference blood samples and blood 
samples from patients, the OzVal-Hb adduct is stable under 
the conditions used here for sampling and processing. 
Moreover, these adducts proved to be stable even after stor-
age of blood at room temperature for 7 days. this stability 
will facilitate routine sampling in the clinic.
In all of the patients treated with CP, the blood level of 
the OzVal-Hb adduct increased after each cycle of dosing 
in the stepwise manner expected. a stable Hb adduct will 
disappear with the same kinetics as the erythrocytes, which 
have a life span of approximately 120 days [10]. thus, if the 
time-points for administration of the drug and sampling are 
known, the relative aUC of the electrophile can be calculated 
from the levels of Hb adduct (see Supplementary Fig. 5).
the 24 % difference between the adduct level in the 
patients in groups a and B following the first administra-























Fig. 5  levels of OzVal-Hb adducts in group a and B following three 
cycles of CP dosing, the values presented are means ± min–max (the 
error bars) for six individuals per group
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(600 vs. 500 mg m−2 BSa, respectively). the more pro-
nounced differences following dosing cycles two and three 
reflect the higher dose administered at shorter intervals 
in the case of group a. the difference in adduct levels 
between the individuals with the highest and lowest values 
was 250 % after the first dose and approximately 150 % 
after each subsequent cycle of dosing. the patients exhibit-
ing lower or higher levels after the first dose continued to 
do so following the second and third dose cycles as well.
Due to the limited number of patients, the obtained data 
for correlations between the OzVal-Hb adduct and hemato-
logic variables (given in Supplementary table 1) should not 
be over interpreted. However, a negative relationship was 
observed in group B who received fixed BSa dosing. these 
patients had also the largest individual variation of the 
OzVal-Hb adduct levels (77–189 pmol g−1 globin) which 
facilitates the search for correlations between biomarker 
level and toxicity in relation to patients in group a who 
were more uniform (121–155 pmol g−1 globin).
the large interindividual variability in capacity to 
metabolize CP to 4-OH-CP has been extensively char-
acterized [3, 19]. Since direct measurement of PaM is 
complicated, previous investigations have involved in the 
determination of its precursor, 4-OH-CP, after cleanup and 
derivatization. Determination of the aUC for 4-OH-CP 
itself has required repeated sampling during the period of 
several hours when the drug is active [3, 19].
Quantification of the OzVal-Hb adduct with the FIRe 
procedure™ as described here provides a novel analyti-
cal tool for the determination of the accumulated blood 
dose of PaM in rBC, a valuable “short-cut” to obtain-
ing the internal dose of the active cytotoxic agent from a 
single blood sample. the small amount of blood needed 
(0.5 ml) also enables applications toward infants and small 
children. this is an important area of research, that due to 
methodical and ethical reasons (by applying conventional 
approaches), consists of limited data. Furthermore, the fact 
that the sample has taken a long time (days) after the drug 
has been excreted, enables measurements at a time that is 
convenient for both the patient and his/her caregivers. the 
next step will be to demonstrate the clinical usefulness of 
this novel approach, and such studies are now ongoing in 
our laboratory.
there are already numerous indications that this 
approach can greatly improve individualization of CP 
dosing. One strategy for overcoming the shortcomings 
of BSa dosing is exemplified by the PantHer study in 
which careful monitoring of the degree of toxic side-effects 
allowed effective adjustment of the dose in well-defined 
steps. With the tailorDose™ strategy proposed here, meas-
urement of the accumulated blood dose of PaM in rBC in 
combination with parameters of toxicity could aid in mak-
ing more precise decisions concerning subsequent dosing 
with CP, as well as concerning whether the dose of only one 
of the drugs in a combination treatment should be altered.
For the individual patient, this means, of course, more 
effective therapy, greater safety and a reduced risk of severe 
side-effects such as immunodepletion. Moreover, the meth-
odology described here can be used to identify pharmacog-
enomic relationships and provide other types of accurate data.
Conclusion
Here, we describe a novel analytical procedure for quantifi-
cation of OzVal-Hb adduct formed from PaM, the cytotoxic 
metabolite of CP. this method was validated and proven to be 
robust in terms of selectivity, stability, accuracy and precision. 
Blood levels of OzVal-Hb adduct in two groups of patients, 
one receiving a constant and the other an increasing dose of 
CP, were clearly related to the dose administered. the adduct 
level rose after each dosing cycle in the manner expected 
for a stable biomarker whose biological half-life follows the 
kinetics of erythrocytes. this approach offers considerable 
promise as a novel clinical tool for accurate determination of 
effective dosing, information that can serve as a basis for indi-
vidual adjustment of the dose of CP, thereby reducing the risk 
of severe side-effects and improving the efficacy of treatment. 
We are now evaluating the clinical value of this new approach 
in a larger study (150 patients), the results of which will be 
published in the near future.
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